** **

**Exhibit10.2**

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THISLICENSE AGREEMENT, MARKED HERE BY ASTERISK, HAS BEEN OMITTED AND FILEDSEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

**LICENSE AGREEMENT**

THIS AGREEMENT is made as of March 1, 2007 (the “Effective Date”) byand between Corgenix Medical Corporation, a Nevada corporation (“Licensee”), onthe one hand, and Creative Clinical Concepts, Inc., a Colorado corporation (“Licensor”),on the other hand.

**PREAMBLE**

A.            Licensor is the soleowner of the trademark “AspirinWorks” (and design) for conducting clinicallaboratory and home use tests to measure aspirin effectiveness, including U.S.Trademark registration No. 2,688,842 for this trademark (the “Licensed Property”).

B.            Licensorpossesses both proprietary and public information related to the available andpotential market for measuring aspirin effectiveness and the use of thromboxaneand prostacyclin metabolites to determine the effect of aspirin on platelets orendothelial cells, including, but not limited to names of contacts, customerlists, market information, competitive information, and technology information(“Market Information”).

C.            Licensee desires toobtain, and the Licensor is willing to grant, a license for use of the LicensedProperty in association with products used in determining the effectiveness ofaspirin and/or anti-platelet therapy (including without limitation, diagnosticproducts used to measure analytes in body fluids to aid in the determination ofthe response of platelets to aspirin ingestion, and any additional productsmeasuring any thromboxane or prostacyclin metabolites for any clinicalcondition) (the “Licensed Products”) on the terms and subject to the conditionsset forth in this Agreement.

D.            Licensor is willingto provide the Market Information to the Licensee to aid Licensee in fulfillingits responsibilities under this Agreement.

**AGREEMENT**

NOW, THEREFORE, in consideration of the above premises and of themutual covenants and conditions herein contained the Parties hereto have agreedand do by these presents agree as follows:

1.             **GRANT OF LICENSE**.

(a)           Licensor hereby grants to theLicensee, and the Licensee hereby accepts, a perpetual and exclusive license tomake, have made, use, and sell, Licensed Products using the Licensed Propertyand to incorporate the Licensed Property into and market and sell 

----

 

such Licensed Propertywith Licensed Products for distribution through retail outlets and otherdistribution channels anywhere in the world (the “Licensed Territory”).  Licensor must not grant any other licensesduring the term of this Agreement for use of the Licensed Property.  For purposes of this Agreement, “AspirinEffectiveness Technology” means technology useful in the development,manufacturing and/or marketing of any products used in determining theeffectiveness of aspirin and/or anti-platelet therapy.  In addition, Licensor hereby conveys the MarketInformation to Licensee, which conveyance shall not be revocable.  The license granted pursuant to this Section1 shall survive any termination of this Agreement by Licensee for breach byLicensor.

(b)           Licensee shall have the right to usethe license granted by Licensor pursuant to this Agreement in connection withany other asset or trademark, trade-name, patent or other intellectual propertyowned or licensed by Licensee related to Aspirin Effectiveness Technology.Licensor shall not use the Licensed Property. The Licensee shall have the right to enter into sublicensing agreementswith any other entity for the rights, privileges, and licenses grantedhereunder, so long as it obtains the prior written consent of the Licensor,which consent shall not be unreasonably withheld, conditioned or delayed byLicensor provided that any such sublicense agreement shall require that thesublicensee will use its commercially best efforts to market and sell theLicensed Products using the Licensed Property. Licensee shall provide Licensorwith at least forty-five days advance written notice of its intent to enterinto a sublicense agreement with any other entity or third party. Licensorshall have forty-five days to advise Licensee as to whether Licensor intends towithhold its consent to such sublicense; provided that such consent may not bewithheld if the Licensed Property is not altered in its presentation byLicensee or sub-licensee and if the Licensed Property is being used inconnection with a Licensed Product.  Inthe event Licensor withholds, conditions or delays its consent and the Licenseebelieves such has been done unreasonably, the parties shall submit the disputeto arbitration for resolution of the dispute. Licensee shall have the solediscretion to use or not use the Licensed Property with respect to anyparticular item of the Licensed Products. Licensee may directly or indirectlyexport Licensed Products using the Licensed Property. Licensor and Licenseeagree the Licensed Property is Intellectual Property as defined inSection 101 (35A) of the United States Bankruptcy Code. Allsublicensees shall be required to market, advertise, and list all LicensedProducts in their fee schedules and promotional materials using the LicensedProperty.

 (c)          Licenseewill use its commercially reasonable best efforts to market and sell theLicensed Products using the Licensed Property. If, in the discretion ofLicensor, reasonably exercised based on objectively verified information anddata, Licensee has not provided its commercially reasonable best efforts,  then Licensor will have the right to notifyLicensee in writing of its desire to convene meetings to discuss a strategy toenhance Net Sales of Licensed Products. Upon receipt of such notice, both parties must meet on no less than two(2) occasions to discuss mutually acceptable solutions to the decline in NetSales of Licensed Products.  If however,the parties are unable to resolve their concerns by meeting at least twice in athirty (30) day period following notice to Licensee, then Licensor may refer thematter to arbitration pursuant to Section 10 below. Failure of  either party to effect or to perform the planset by the Arbitrator shall constitute a material breach of this Agreement.

2

----

 

(d)           Licensee shall forgive all unpaidpast, present and future product development fees, costs and expenses, and allunpaid  fees, costs and expenses relatedthereto, due from Licensor to Licensee pursuant to that certain ProductDevelopment, Manufacturing and Distribution Agreement dated May 13, 2004, andLicensee shall forgive all unpaid fees, costs, expenses and charges includingall future fees, costs, expenses and charges related to the McMaster Universitypatent and license due from Licensor to McMaster University pursuant to thatcertain License Agreement dated October 19, 2004. For accounting purposes, theLicensee shall treat said forgiveness as an additional cost of the License.

(e)           Within ninety days from the date FDAclearance is obtained for the Licensed Products and for a period of five yearsthereafter, Licensee shall, at its sole expense, develop and maintain anup-to-date and interactive internet website dedicated to the Licensed Productsto enable customers and potential customers to access information related toobtaining, buying, understanding and using the Licensed Products. Licensorshall cooperate as necessary to assist Licensee in the development andmaintenance of such website to assure that accurate information is available tocustomers and potential customers as to the Licensed Products.

2.             **TERM AND TERMINATION**.

(a)           The term of this Agreement (“Term”)shall commence as of the Effective Date and shall continue in perpetuity unlessproperly terminated by either party as set forth in paragraph 2(c) following abreach of this Agreement by the other party~~,~~.

(b)           Upon termination of this Agreement bythe Licensor, (i) Licensee shall have the right to sell the Licensed Productsthat have been contracted for sale by the Licensee  prior to the date of termination for suchperiod of time (the “Sellout Period”) as is required to complete the sale ofsuch Licensed Products and shall pay Licensor royalties on the sales of suchLicensed Products during the Sellout Period in accordance with the provisionsof this Agreement; and (ii) except for Licensee’s right to dispose of LicensedProducts as set forth in clause (i) above, (1) Licensee shall release all ofLicensee’s rights in and to the Licensed Property and the license grantedpursuant to this Agreement; and (2) all rights of Licensee in and to theLicensed Property shall revert to Licensor, except for any rights sublicensedto a third party, which rights will not be revocable or infringed as a resultof the termination of this Agreement, and Licensee must make appropriatearrangements with any sublicensee at that time. Upon termination of thisAgreement by the Licensee, all fees and royalties will be terminated effectiveimmediately.

(c)           Either party may terminate thisAgreement if a material breach of this Agreement by the other party is notcured within thirty (30) days following written notice to the other partyspecifying the default; provided that no termination may occur unless and untilthe underlying dispute has been arbitrated and either party has violated in anymaterial respect the plan or order of the arbitrator.  Notwithstanding the foregoing, if, followingarbitration, the breaching party is diligently pursuing cure of the default,but is not able to cure the default within the thirty (30) day period, the cureperiod shall be extended for an additional thirty (30) days.

(d)           This Agreement shall terminate if theLicensee becomes insolvent or files for protection or relief under anyprovision of the United States Bankruptcy Code. In 

3

----

 

such event, the parties agree that the Licensor shallbe entitled to relief from stay in any such bankruptcy proceeding, withoutcontest by Licensee, in order to allow Licensor to terminate this agreement. Insuch event all rights of Licensee in and to the Licensed Property shall revertto the Licensor.

3.             **LICENSE FEES**.  As consideration for the license grantedherein, and for such time as the Licensor is not in breach of, or deemed to bein breach of, its obligations hereunder, the Licensee agrees to pay theLicensor license fees in a combination of cash, shares of common stock of theLicensee (“Corgenix Shares”), and warrants to purchase Corgenix Shares (“CorgenixWarrants”) as described in this Section 3. The payments outlined in this Section 3 are subject in all events to thelimitations in Section 3(e).

(a)           On the EffectiveDate, Licensee will pay Licensor:

(i)            $50,000 in cash;

(ii)           a number of Corgenix Shares equal to$75,000 divided by the greater of (a) the average closing price of the CorgenixShares on the OTC:BB during the five trading days immediately preceding theEffective Date and (b) [***] (the “Calculated Price”); and

(iii)          75,000 Corgenix Warrants with anexercise price equal to the Calculated Price.

(b)           On the firstanniversary of Corgenix receiving FDA clearance of the first Licensed Product(the “First Anniversary”), Licensee will pay to Licensor:

(i)            A cash payment equal to $50,000multiplied by the First Anniversary Ratio, where:

a.              First Anniversary Ratio meansTotal Cumulative Revenue divided by [***]; and

b.             Total Cumulative Revenue meansLicensee’s net sales revenue from all Licensed Products calculated from theEffective Date through the First Anniversary.

(ii)           a number ofCorgenix Shares equal to the product of:

a.             $75,000 divided by the greater of(i) the average closing price of the Corgenix Shares on the OTC:BB during thefive trading days immediately preceding the First Anniversary and (ii) [***](the “First Anniversary Calculated Price”)

4

----

 

Multiplied by

b.             the First Anniversary Ratio.

(iii)          75,000 Corgenix Warrants with anexercise price equal to First Anniversary Calculated Price.

(c)           On the secondanniversary of Corgenix receiving FDA clearance of the first Licensed Product(the “Second Anniversary”), Licensee will pay to Licensor:

(i)            A cash payment equal to $50,000multiplied by the Second Anniversary Ratio, where:

a.              Second Anniversary Ratio meansTotal Cumulative Revenue divided by [***]; and

b.             Total Cumulative Revenue meansLicensee’s net sales revenue from all Licensed Products calculated from theEffective Date through the Second Anniversary.

(ii)           a number ofCorgenix Shares equal to the product of:

a.             $75,000 divided by the greater of(i) the average closing price of the Corgenix Shares on the OTC:BB during thefive trading days immediately preceding the Second Anniversary and (ii) [***](the “Second Anniversary Calculated Price”)

Multiplied by

b.             the SecondAnniversary Ratio.

(iii)          75,000 Corgenix Warrants with anexercise price equal to the  SecondAnniversary Calculated Price.

(d)           On the thirdanniversary of Corgenix receiving FDA clearance of the first Licensed Product(the “Third Anniversary”), Licensee will pay to Licensor:

(i)            A cash payment equal to $50,000multiplied by the Third Anniversary Ratio, where:

a.            Third Anniversary Ratio means Total Cumulative Revenue divided by [***]; and

b.             TotalCumulative Revenue means Licensee’s net sales revenue from all LicensedProducts calculated from the Effective Date through the Third Anniversary.

5

----

 

(ii)           a number of Corgenix Shares equal tothe product of:

a.             $75,000divided by the greater of (i) the average closing price of the Corgenix Shareson the OTC:BB during the five trading days immediately preceding the ThirdAnniversary and (ii) [***] (the “Third Anniversary Calculated Price”).

Multiplied by

b.             the Third Anniversary Ratio.

(iii)                               75,000Corgenix Warrants with an exercise price equal to the  Third Anniversary Calculated Price.

(e)           Notwithstanding theprovisions of Sections 3(a)-(d) above:

(i)            the total amount of cash paid toLicensor pursuant to this Section 3 will not exceed $200,000;

(ii)           the total number of Corgenix Sharesissued to Licensor pursuant to this Section 3 will not exceed $300,000 inaggregate market value (with Corgenix Shares valued as of the dates suchCorgenix Shares are issued);

(iii)          the total number of Corgenix Warrantsissued to Licensor pursuant to this Section 3 will not exceed 300,000; and

(iv)          no cash, Corgenix Shares, or CorgenixWarrants will be paid or issued after the Third Anniversary except as providedin Section 4.

4.             **ROYALTIES AND REPORTS**.

(a)           As additionalconsideration for the perpetual license herein granted, the Licensee agrees topay the Licensor earned royalties of: seven percent (7%) of aggregate “NetSales of Licensed Products” received by the Licensee or any affiliate ofLicensee from third parties for a period beginning on the Effective Date andterminating ten (10) years later.  Allsuch royalties shall be paid by Licensee to Licensor within fifteen days afterthe end of each calendar quarter based on the proceeds of Net Sales of LicensedProducts collected by Licensee during the immediately preceding calendarquarter.  For purposes of this Agreement,“Net Sales of Licensed Products” shall mean the total amounts received byLicensee (or any affiliate of Licensee) from third party purchasers on allsales by Licensee (or any affiliate of Licensee) of Licensed Products, afterdeducting, to the extent not already deducted, normal and customary trade,dealer, quantity, and cash discounts actually allowed; freight charges;customary trade discounts actually taken; allowances for credits granted onaccount of Licensed Products rejections, 

6

----

 

returns, or price reductions; governmental sales,consumption and other taxes and  chargesimposed on sales of Licensed Products; non payment of invoices in accordancewith their terms; and freight, insurance, customs, duties, and other landingcharges.  If payments to Licensee or anyaffiliate of Licensee are made in currency other than United States Dollars,then such currency shall be converted into its equivalent in United StatesDollars at the rates used by Licensee in its internal accounting procedures.

(b)           Within thirty (30)days after the end of any quarter during the Term of this Agreement and theSellout Period, together with the payment of any royalty required to be paidpursuant to this Agreement by Licensee to Licensor, the Licensee shall reportto the Licensor all royalties accruing under this Agreement during suchquarter.  Such reports shall indicate forsuch quarter the aggregate payments on Net Sales of Licensed Products receivedby the Licensee by item, and shall indicate the amount of the royalty due andthe manner in which such amount is determined. In case no royalty is due for any such quarter, the Licensee shall soreport and shall provide an accounting as to how Licensee determined no royaltyis due.

(c)           The Licensee shallkeep accurate records in sufficient detail to enable royalties due hereunder tobe determined, in accordance with generally accepted accounting principles,consistently applied.  Upon the Licensor’srequest, and only after signing an appropriate confidentiality agreement, theLicensee shall permit an independent auditor selected by the Licensor and atLicensor’s sole expense to have access annually, upon the Licensor’s request,during the Term hereof, during regular business hours and upon reasonablenotice (which shall be at least 5 business days) to the Licensee as may bereasonably necessary to: (1) verify the accuracy of reports made under thisAgreement since the prior audit, and (2) determine insolvency of the Licenseeunder section 2(d).  All informationobtained by Licensor in any such audit shall be kept strictly confidential byLicensor and Licensor’s auditors and may not be used by Licensor or any otherperson or entity for any reason whatsoever other than calculating amountspayable to Licensor pursuant to this Agreement and shall not be divulged byLicensor or its auditors to any person or entity other than to Licensor’sattorneys, accountants, and as required by applicable law.  Licensee shall maintain all accountinginformation relating to any royalty payment to Licensor pursuant to thisAgreement for three (3) years following the date of any such royaltypayment.  The provisions of thisSection shall survive termination of this Agreement.

5.             **MANUFACTURE**.

(a)           Licensee shall beresponsible for the manufacture, distribution and administration of the sale ofthe Licensed Products at all times, including all costs relating thereto.

(b)           Licensor shallassist and cooperate with Licensee, as reasonably requested by Licensee, inconnection with the manufacture of Licensed Products.  Licensor shall share with Licensee allinformation in Licensor’s possession regarding manufacturers, including,without limitation, factory names, contact information and current costinformation.

7

----

 

(c)           Subject to thatcertain Consulting Agreement between Licensee and Gordon Ens of even dateherewith and any other consulting or other agreement which may affect theLicensor’s business or day to day operations thereof, Licensor and its agents,attorneys, officers, directors, members, partners, shareholders, employees,consultants and representatives shall not interfere with Licensee’s business inany manner whatsoever, including, but not limited to, Licensee’s day to dayoperations, administrative procedures, sales procedures, accounting methods,personnel and customers, and shall not contact any of Licensee’s vendors,suppliers, licensors, licensees or customers relating to the subject matter ofthis Agreement and/or the Licensed Products without Licensee’s prior writtenconsent or discuss this Agreement with any person or entity (other than its ownemployees and agents) without Licensee’s prior written consent.

(d)           Licensee shallcomply with standards of quality control reasonably established by Licensor inconnection with offering of the Licensed Products in order to protect andmaintain the goodwill of Licensor associated with the trademark. Licensee shalluse only a form and style of the trademark as approved by Licensor. Licensorshall have the right to inspect and supervise the Licensee’s manufacture ofLicensed Products bearing the trademark, for the purpose of protecting andmaintaining the goodwill of Licensor associated with the trademark.

6.             **LICENSOR’S NEW PRODUCT DEVELOPMENT**.

(a)           In the event Licensor,either directly or through any affiliate of Licensor, develops any new productsfor measuring aspirin effectiveness and the use of thromboxane and prostacyclinmetabolites to determine the effect of aspirin on platelets or endothelialcells, that Licensor (or affiliate) desires to distribute, Licensor shall givewritten notice thereof to Licensee, which notice shall include all informationin Licensor’s possession or control relating to the development, manufactureand sale of the new products.  Licenseeshall have ninety (90) days after receipt of Licensor’s notice within which toadvise Licensor in writing of Licensee’s interest in obtaining a license fromLicensor for the new products.  Thelicense shall be on substantially the same terms as this Agreement, except thatLicensor shall negotiate in good faith with Licensee with respect to theroyalty.  If  Licensor and Licensee are not able to reachagreement on the royalty within ninety (90) days after Licensor’s receipt ofLicensee’s notice, Licensor shall have the right to enter into a license withanother party; provided that the royalty provisions shall not be more favorableto the licensee than the provisions offered by Licensor to Licensee; andfurther provided, that Licensor offers Licensee the right for a period of ten(10) days after written notice from Licensor (which notice shall include a copyof the proposed license) to enter into a license agreement with Licensor forthe new products on the terms of the proposed license with the other party(i.e. a right of first refusal).

(b)           The provisions ofparagraph 6(a) will not be applicable to new products distributed without theuse of the Licensed Property. However, prior to pursuing the distribution ofthe new products in such manner, either on its own or with another party,Licensor shall discuss the distribution arrangements with Licensee for thepurpose 

8

----

 

of determining if there is a mutually agreeablearrangement between Licensor and Licensee for distribution of the products.

7.             **REPRESENTATIONS,WARRANTIES AND COVENANTS**.

(a)           Licensor represents,warrants and covenants to Licensee as follows: (i) Licensor owns allrights in and to the Licensed Property free and clear of all liens andencumbrances; (ii) Licensor has the full right, authority and power toenter into this Agreement and to perform all its obligations hereunder;(iii) Licensor’s execution, delivery and performance of this Agreementwill not violate the provisions of any agreement to which Licensor is a party;and (iv) the Licensed Property does not infringe upon the intellectualproperty rights of any other party. Neither Licensor nor Licensee makes any representation or warranty as tothe amount of receipts Licensee will derive from, or as to the quality orsuccess of, the Licensed Products.

(b)           Licensee representsand warrants to Licensor as follows: (i) Licensee has full power andauthority to enter into this Agreement and perform its obligations herein; and(ii) Licensee’s execution, delivery and performance of this Agreement willnot violate the provisions of any agreement to which Licensee is a party.

8.             **INDEMNIFICATION**. Licensor shall indemnify, hold harmless and defend Licensee, and itsparents, subsidiaries, affiliates, officers, directors and employees, againstany claims, liabilities, demands, causes of action, judgments, settlements andexpenses (including, but not limited to, reasonable attorneys’ fees and courtcosts) arising out of or related to Licensee’s use of the Licensed Property asauthorized hereunder, including as a result of the infringement or allegedinfringement of any of the Licensed Property on the intellectual propertyrights of any person or entity resulting from Licensee’s manufacture or sale ofLicensed Products using the Licensed Property.

9.             **NOTICE**.

(a)           All notice(s) ofevery kind and description whatsoever under this Agreement shall be in writingand shall be deemed to have been received when personally delivered or whenmailed through the U.S. Postal Service, postage prepaid, return receipt requested,or when shipped by private express carrier, shipment charges prepaid, to theparty to whom delivery shall be made at the respective addresses as set outbelow.

| To Licensor: |   | Creative Clinical Concepts, Inc.                         |
|--------------|--------|----------------------------------------------------------|
|         |   | 224 East Cedar Ridge Court                               |
|         |   | Andover, Kansas 67002                                    |
|         |   |                                                     |
| To Licensee: |   | Corgenix Medical Corporation                             |
|         |   | 11575 Main Street, Suite 400  Broomfield, Colorado 80020 |

 

9

----

 

 

| With a copy to: |   | Robert P. Attai  Otten, Johnson, Robinson, Neff &  Ragonetti, P.C.  950 17th Street  Denver, CO 80202 |
|-----------------|--------|----------------------------------------------------------------------------------------------------------------|

 

10.           **ARBITRATION**.  Subject to Section 1(c), the parties agree tosubmit to binding arbitration any and all claims, disputes and controversiesbetween or among them relating to this Agreement.  Arbitration must proceed in Denver, Colorado,be governed by Colorado law, and be conducted in accordance with the CommercialArbitration Rules of the American Arbitration Association (“AAA”).  Judgment upon the award rendered by the arbitratorsmay be entered in any court having jurisdiction.  Arbitration must be before a single, neutralarbitrator with at least 10 years of experience in commercial business dealingsinvolving medical technology.  The AAAshall submit a list of persons meeting the criteria outlined above and theparties must select the arbitrator in the manner established by the AAA.  The arbitrator will not be authorized torevoke the license granted pursuant to Section 1 of this agreement, but will beauthorized to revoke Licensee’s exclusivity with respect to such LicensedProperty.

11            **MISCELLANEOUS**.

(a)           This Agreementconstitutes the entire understanding between the parties hereto relating to thesubject matter of this Agreement. This agreement supplements, but does notsupersede the Product Development, Manufacturing and Distribution Agreementbetween the parties, dated May 13, 2004.

(b)           No provision of thisAgreement may be amended or added to except by an agreement in writing signedby all of the parties hereto.

(c)           This Agreement andthe rights, obligations and duties hereunder shall not be assigned by any partywithout the prior written consent of the other party, except in connection withthe sale or other transfer by the party of all or substantially all of the party’sbusiness and assets in a transaction in which the transferee agrees in writingto be bound by all of the terms of this Agreement. This Agreement shall bebinding on the parties, their successors, sublicensees, assigns, affiliates andfiduciaries.

(d)           This Agreement shallbe governed by the laws of State of Colorado (without regard to its so-calledchoice of law rules).

(e)           Any provision ofthis Agreement which is unenforceable in any jurisdiction shall, as to suchjurisdiction, be ineffective only to the extent of such unenforceabilitywithout invalidating the remaining provisions of this Agreement or affectingthe enforceability of such provision in any other jurisdiction.

(f)            The descriptiveheadings of this Agreement are intended for reference only and shall not affectthe construction or interpretation of this Agreement.

10

----

 

(g)           No forbearance,delay or indulgence by either party in enforcing the provisions of thisAgreement shall prejudice or restrict the rights of that party, nor shall anywaiver of its rights operate as a waiver of any subsequent breach.

(h)           The parties will,without further consideration, do any further acts and deliver all furtherassurances, documents, as shall be necessary or required to fully perform andcarry out the terms of this Agreement.

(i)            The parties haveentered into this Agreement as independent contractors only, and nothingcontained in this Agreement places or shall be construed to place the partiesin the relationship of legal representation, employer-employee, partners, jointventurers, or agency, and neither party will have the power or authority toobligate or bind the other party in any manner. There is no intent to create third party beneficiary status in any otherperson and no third party shall have any right to enforce any provision hereof.

(j)            In the event eitherparty commences any legal action to enforce the provisions of this Agreementfollowing a breach thereof by the other party, the prevailing party in suchaction shall be entitled to recover from the other party, in addition to anyother legal or equitable relief granted, all reasonable attorneys’ fees andcosts in such action.

(k)           This Agreement maybe executed in one or more counterparts, all of which, together, shall bedeemed one and the same original document.

(l)            This Agreement shall be effective onthe date of execution of this Agreement by the parties, which date shall be theEffective Date as referred to in the provisions set forth in this Agreement.

11

----

 

IN WITNESS WHEREOF, the parties have executed thisAgreement as of the Effective Date.
|            | ** ** | **LICENSEE**                      |
|------------|------------|-----------------------------------|
| ** ** | ** ** | ** **                        | ** ** | ** ** |
|       |       | Corgenix Medical Corporation      |
|       |       |                              |   |   |
|       |       | By:                               |   | /s/ Douglass T. Simpson |
|       |       |                              |   | Douglass T.  Simpson |
|       |       |                              |   | President and  CEO |
|       |       |                              |   |   |
| ** ** |       | **LICENSOR**                      |
|       |       | Creative  Clinical Concepts, Inc. |
|       |       |                              |   |   |
|       |       | By:                               |   | /s/ Gordon E. Ens |
|       |       |                              |   | Gordon E. Ens |
|       |       |                              |   | President |

 

12

----

 

**EXHIBIT A**

**LICENSEDPROPERTY**

1.               Trademarksdepicted on Exhibit A-1

2.               Allrights under the License Agreement with McMaster University dated October 19,2004, attached hereto as Exhibit A-2

13

----